Madrigal (NASDAQ: MDGL) insider plans Rule 144 sale after recent stock sales

Rhea-AI Filing Summary

Madrigal Pharmaceuticals insider plans a small stock sale under Rule 144. A person associated with the company filed to sell 340 shares of common stock through Morgan Stanley Smith Barney at an aggregate market value of $163,353 on or about January 26, 2026 on the Nasdaq Stock Market.

The shares come from a restricted stock unit grant that vested on January 23, 2026. Over the prior three months, Carole Huntsman reported additional sales of Madrigal common stock totaling 2,528 shares for gross proceeds of $1,365, - across three transactions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	340	163353	22711420	01/26/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/23/2026	Restricted Stock Unit Grant	Issuer			340	01/23/2026	Vesting of Restricted Stock Units

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Carole Huntsman c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	01/26/2026	570	281916.3
Carole Huntsman c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	11/21/2025	1064	590419.03
Carole Huntsman c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	11/21/2025	894	492567.18

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for MDGL disclose?

The filing discloses a planned sale of 340 shares of Madrigal Pharmaceuticals common stock, with an aggregate market value of $163,353, to be sold on or about January 26, 2026 under Rule 144.

Who is the seller in the latest MDGL Rule 144 notice and what is their relationship?

The seller is identified as Carole Huntsman, listed c/o Madrigal Pharmaceuticals, Inc., indicating a person associated with the company whose shares are being sold under Rule 144.

How were the 340 MDGL shares being sold acquired?

The 340 shares of Madrigal common stock were acquired on January 23, 2026 through a restricted stock unit grant, with the shares delivered upon the vesting of those restricted stock units.

Which broker is handling the MDGL insider’s planned sale?

The planned sale of 340 shares of Madrigal common stock will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services in New York.

On which exchange are the MDGL shares being sold and how many are outstanding?

The shares are listed for sale on the Nasdaq Stock Market. The filing notes that 22,711,420 shares of Madrigal common stock were outstanding at the time of the notice.

What MDGL stock sales has Carole Huntsman made in the past three months?

Over the past three months, Carole Huntsman sold Madrigal common stock in three transactions: 570 shares for $281,916.30 on January 26, 2026, 1,064 shares for $590,419.03, and 894 shares for $492,567.18 on November 21, 2025.